for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Constellation Pharmaceuticals Inc

CNST.OQ

Latest Trade

34.00USD

Change

0.53(+1.58%)

Volume

72,441

Today's Range

32.85

 - 

34.86

52 Week Range

6.09

 - 

59.14

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Constellation Pharmaceuticals Reports Q1 Loss Per Share $0.61

May 6 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS ANNOUNCES FIRST-QUARTER 2020 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.61.Q1 EARNINGS PER SHARE ESTIMATE $-0.62 -- REFINITIV IBES DATA.CONSTELLATION PHARMACEUTICALS - EXPECTS CURRENT CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES WILL ENABLE IT TO FUND OPERATIONS INTO H2 OF 2022.

Constellation Pharmaceuticals Announces Q4 Loss Per Share $0.69

March 10 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.69.Q4 EARNINGS PER SHARE ESTIMATE $-0.69 -- REFINITIV IBES DATA.CONSTELLATION PHARMACEUTICALS SEES CURRENT CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES WILL ENABLE CO TO FUND OPERATIONS INTO H22022.

Constellation Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Dec 10 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 6.50 MILLION COMMON SHARES PRICED AT $34.50PER SHARE.

Constellation Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Dec 9 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CONSTELLATION PHARMACEUTICALS INC - HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF 4.75 MILLION SHARES OF ITS COMMON STOCK.

Constellation Pharmaceuticals Provides Updated Preliminary Data From Manifest Clinical Trial With CPI-0610 In Oral & Poster Presentations At Ash

Dec 9 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS PROVIDES UPDATED PRELIMINARY DATA FROM MANIFEST CLINICAL TRIAL WITH CPI-0610 IN ORAL AND POSTER PRESENTATIONS AT ASH.CONSTELLATION PHARMACEUTICALS INC - CPI-0610 IN COMBINATION WITH RUXOLITINIB IN JAK-INHIBITOR-NAÏVE PATIENTS WAS GENERALLY WELL TOLERATED.CONSTELLATION PHARMACEUTICALS- CPI-0610 AS MONOTHERAPY OR WITH RUXOLITINIB IN RUXOLITINIB-REFRACTORY OR -INTOLERANT PATIENTS GENERALLY WELL TOLERATED.CONSTELLATION PHARMACEUTICALS INC - PIVOTAL PHASE 3 CLINICAL TRIAL STUDYING COMBINATION OF CPI-0610 EXPECTED TO START IN 2020.

Constellation Pharma Announces Q3 Loss Per Share $0.82

Nov 6 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS ANNOUNCES THIRD-QUARTER AND NINE-MONTH 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.82.Q3 EARNINGS PER SHARE ESTIMATE $-0.83 -- REFINITIV IBES DATA.CONSTELLATION PHARMACEUTICALS - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES AS OF SEPTEMBER 30, 2019, WERE $89.1 MILLION, DECLINE OF 22.3%.QTRLY NET LOSS OF $0.82 PER SHARE.

Constellation Pharmaceuticals Announces $65 Million Private Placement With New And Existing Investors

Oct 1 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS ANNOUNCES $65 MILLION PRIVATE PLACEMENT WITH NEW AND EXISTING INVESTORS.CONSTELLATION PHARMACEUTICALS INC - COMPANY IS SELLING 7.6 MILLION SHARES OF COMMON STOCK AT A PRICE OF $8.50 PER SHARE.CONSTELLATION PHARMACEUTICALS - TO USE NET PROCEEDS TO FUND RESEARCH AND DEVELOPMENT EXPENSES, TO ADVANCE CURRENT PIPELINE OF PRECLINICAL CANDIDATES.CONSTELLATION PHARMACEUTICALS INC - PRIVATE PLACEMENT IS BEING LED BY VENROCK HEALTHCARE CAPITAL PARTNERS.CONSTELLATION PHARMACEUTICALS INC - PRIVATE PLACEMENT INCLUDES BAIN CAPITAL LIFE SCIENCES AND AFFILIATES OF COLUMN GROUP.

Constellation Pharmaceuticals Q2 Loss Per Share $0.80

Aug 7 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS ANNOUNCES SECOND-QUARTER AND SIX-MONTH 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.80.Q2 EARNINGS PER SHARE ESTIMATE $-0.81 -- REFINITIV IBES DATA.PROSTAR STUDY OF CPI-1205 REMAINS ON TRACK, AND IND FOR CPI-0209 WAS FILED AND CLEARED BY FDA.EZH2 FRANCHISE CONTINUES TO ADVANCE.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES AS OF JUNE 30, 2019, WERE $98.1 MILLION.

Constellation Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln

Aug 2 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.

Constellation Pharmaceuticals Q1 Loss Per Share $0.75

May 8 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS ANNOUNCES FIRST-QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.75.Q1 EARNINGS PER SHARE ESTIMATE $-0.80 -- REFINITIV IBES DATA.CONSTELLATION PHARMACEUTICALS - CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AS OF MARCH 31, 2019, UP 1.0% COMPARED TO DEC 31, 2018, TO $115.8 MILLION.CONSTELLATION PHARMACEUTICALS - SEES CASH,CASH EQUIVALENTS, MARKETABLE SECURITIES AS OF MARCH 31, 2019, TO FUND OPERATING EXPENSES & CAPEX TO Q3 2020.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up